GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Significant Growth in Short Interest

GeoVax Labs, Inc. (NASDAQ:GOVX) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 511,200 shares, an increase of 6.5% from the November 30th total of 479,800 shares. Based on an average daily trading volume, of 1,640,000 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC acquired a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs at the end of the most recent reporting period. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Stock Up 1.2 %

NASDAQ GOVX traded up $0.03 during trading on Wednesday, hitting $2.47. The stock had a trading volume of 1,947,878 shares, compared to its average volume of 2,317,359. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The stock has a 50 day simple moving average of $2.39 and a 200 day simple moving average of $2.81.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same period in the prior year, the business posted ($4.80) earnings per share. Research analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a report on Friday, November 15th. Alliance Global Partners started coverage on GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a report on Wednesday, December 18th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.